Madrigal Pharmaceuticals, Inc. - Common Stock (MDGL)
376.89
+7.05 (1.91%)
NASDAQ · Last Trade: Aug 18th, 2:48 PM EDT
Detailed Quote
Previous Close | 369.84 |
---|---|
Open | 354.56 |
Bid | 376.14 |
Ask | 377.00 |
Day's Range | 351.31 - 376.89 |
52 Week Range | 200.63 - 377.46 |
Volume | 469,724 |
Market Cap | 6.45B |
PE Ratio (TTM) | -29.61 |
EPS (TTM) | -12.7 |
Dividend & Yield | N/A (N/A) |
1 Month Average Volume | 420,903 |
Chart
About Madrigal Pharmaceuticals, Inc. - Common Stock (MDGL)
Madrigal Pharmaceuticals is a biopharmaceutical company focused on developing innovative therapeutics for liver and metabolic diseases, with an emphasis on addressing non-alcoholic steatohepatitis (NASH) and related conditions. The company’s research and development efforts center around its proprietary drug candidates that target and modulate key metabolic pathways, aiming to improve patient outcomes and provide effective treatment options. By leveraging cutting-edge science and clinical expertise, Madrigal is dedicated to advancing its pipeline of transformative therapies to meet the growing needs of patients suffering from complex liver diseases. Read More
News & Press Releases
The FDA will allow patients with MASH to undergo Wegovy treatment, hampering the only other company with an approved MASH drug.
Via Investor's Business Daily · August 18, 2025
FDA approves Novo Nordisk's Wegovy for MASH with liver fibrosis, supported by ESSENCE trial data as the company projects lower 2025 sales growth.
Via Benzinga · August 18, 2025
John Paulson's hedge fund discloses the purchase of 9,000 shares of Alphabet.
Via Benzinga · August 16, 2025
Madrigal Pharmaceuticals (MDGL) beats Q2 2025 revenue estimates with $212.8M, driven by strong Rezdiffra sales, narrowing losses. Stock rises 12.8% pre-market.
Via Chartmill · August 5, 2025
Rezdiffra wins CHMP backing for conditional EU approval in MASH with fibrosis; decision from European Commission expected in August.
Via Benzinga · June 20, 2025
Via The Motley Fool · May 13, 2025
Despite soaring short interest, retail sentiment remains bullish, with investors optimistic about the company’s positive trial results and the continued demand for its FDA-approved treatment, Rezdiffra.
Via Stocktwits · May 11, 2025
Via Benzinga · April 30, 2025
Via Benzinga · April 25, 2025

Via Benzinga · February 26, 2025

Via Benzinga · February 26, 2025

Madrigal's Rezdiffra showed significant liver stiffness reduction in MASH cirrhosis. The company also beat Q4 earnings and revenue expectations.
Via Benzinga · February 26, 2025

Via The Motley Fool · January 17, 2025

Novo Nordisk A/S is moving closer to adding more sales for its blockbuster GLP-1 drug semaglutide to treat a chronic liver disease.
Via MarketBeat · December 18, 2024

Via The Motley Fool · November 25, 2024

Via The Motley Fool · November 23, 2024